{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:19:43Z","timestamp":1773659983335,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002943","name":"Departament d&apos;Innovaci&amp;#x00F3;, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2014SGR354"],"award-info":[{"award-number":["2014SGR354"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002943","name":"Departament d&apos;Innovaci&amp;#x00F3;, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2013FI_B1076"],"award-info":[{"award-number":["2013FI_B1076"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002943","name":"Departament d&apos;Innovaci&amp;#x00F3;, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2014SGR354"],"award-info":[{"award-number":["2014SGR354"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002943","name":"Departament d&apos;Innovaci&amp;#x00F3;, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2014SGR354"],"award-info":[{"award-number":["2014SGR354"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA16223"],"award-info":[{"award-number":["CA16223"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One of the most severe complications after successful cancer therapy is the development of therapy-related myeloid neoplasms (t-MN). Constitutional genetic variation is likely to impact on t-MN risk. We aimed to evaluate if polymorphisms in the p53 pathway can be useful for predicting t-MN susceptibility. First, an association study revealed that the Pro variant of the<jats:italic>TP53<\/jats:italic>Arg72Pro polymorphism and the G allele of the<jats:italic>MDM2<\/jats:italic>SNP309 were associated with t-MN risk. The Arg variant of<jats:italic>TP53<\/jats:italic>is more efficient at inducing apoptosis, whereas the Pro variant is a more potent inductor of cell cycle arrest and DNA repair. As regards<jats:italic>MDM2<\/jats:italic>SNP309, the G allele is associated with attenuation of the p53 apoptotic response. Second, to evaluate the biological effect of the<jats:italic>TP53<\/jats:italic>polymorphism, we established Jurkat isogenic cell lines expressing p53Arg or p53Pro. Jurkat p53Arg cells presented higher DNA damage and higher apoptotic potential than p53Pro cells, after treatment with chemotherapy agents. Only p53Pro cells presented t(15;17) translocation and del(5q). We suggest that failure to repair DNA lesions in p53Arg cells would lead them to apoptosis, whereas some p53Pro cells, prone to cell cycle arrest and DNA repair, could undergo misrepair, generating chromosomal abnormalities typical of t-MN.<\/jats:p>","DOI":"10.1038\/s41598-018-36931-x","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T07:26:19Z","timestamp":1547191579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms"],"prefix":"10.1038","volume":"9","author":[{"given":"Maria","family":"Cabezas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Garc\u00eda-Quevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cintia","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Manubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Francesc","family":"Barquinero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-1390","authenticated-orcid":false,"given":"Santiago","family":"Ram\u00f3n y Cajal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adoraci\u00f3n","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Rosa","family":"Caball\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2345-1106","authenticated-orcid":false,"given":"Gemma","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"36931_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"36931_CR2","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","volume":"121","author":"LM Morton","year":"2013","unstructured":"Morton, L. M. et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008. Blood 121, 2996\u20133004 (2013).","journal-title":"Blood"},{"key":"36931_CR3","doi-asserted-by":"publisher","unstructured":"Morton, L. M., Onel, K., Curtis, R. E., Hungate, E. a & Armstrong, G. T. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am. Soc. Clin. Oncol. Educ. Book e57\u201367, https:\/\/doi.org\/10.14694\/EdBook_AM.2014.34.e57 (2014).","DOI":"10.14694\/EdBook_AM.2014.34.e57"},{"key":"36931_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","volume":"35","author":"LA Godley","year":"2008","unstructured":"Godley, L. A. & Larson, R. A. Therapy-Related Myeloid Leukemia. Semin. Oncol. 35, 418\u2013429 (2008).","journal-title":"Semin. Oncol."},{"key":"36931_CR5","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser, S. et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117, 2137\u20132145 (2011).","journal-title":"Blood"},{"key":"36931_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","volume":"102","author":"SM Smith","year":"2003","unstructured":"Smith, S. M. et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102, 43\u201352 (2003).","journal-title":"Blood"},{"key":"36931_CR7","first-page":"973","volume":"8","author":"DG Leonard","year":"2002","unstructured":"Leonard, D. G. et al. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 8, 973\u2013985 (2002).","journal-title":"Clin Cancer Res"},{"key":"36931_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.leu.2403187","volume":"18","author":"C Schoch","year":"2004","unstructured":"Schoch, C., Kern, W., Schnittger, S., Hiddemann, W. & Haferlach, T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18, 120\u2013125 (2004).","journal-title":"Leukemia"},{"key":"36931_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.leu.2405078","volume":"22","author":"J Pedersen-Bjergaard","year":"2008","unstructured":"Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T. & Christiansen, D. H. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 22, 240\u2013248 (2008).","journal-title":"Leukemia"},{"key":"36931_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/10428190701769657","volume":"49","author":"V Guillem","year":"2008","unstructured":"Guillem, V. & Tormo, M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk. Lymphoma 49, 204\u201317 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"36931_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.dnarep.2014.03.009","volume":"19","author":"ZD Nagel","year":"2014","unstructured":"Nagel, Z. D., Chaim, I. A. & Samson, L. D. Inter-individual variation in DNA repair capacity: A need for multi-pathway functional assays to promote translational DNA repair research. DNA Repair (Amst). 19, 199\u2013213 (2014).","journal-title":"DNA Repair (Amst)."},{"key":"36931_CR12","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.2011.34.6585","volume":"29","author":"GT Armstrong","year":"2011","unstructured":"Armstrong, G. T. et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study. J. Clin. Oncol. 29, 3056\u20133064 (2011).","journal-title":"J. Clin. Oncol."},{"key":"36931_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.29096","volume":"121","author":"S Bhatia","year":"2015","unstructured":"Bhatia, S. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Cancer 121, 648\u2013663 (2015).","journal-title":"Cancer"},{"key":"36931_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.leu.2401660","volume":"14","author":"MH Woo","year":"2000","unstructured":"Woo, M. H. et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 14, 232\u20137 (2000).","journal-title":"Leukemia"},{"key":"36931_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/00008571-200211000-00004","volume":"12","author":"JG Blanco","year":"2002","unstructured":"Blanco, J. G. et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 12, 605\u201311 (2002).","journal-title":"Pharmacogenetics"},{"key":"36931_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.leukres.2004.11.001","volume":"29","author":"M Collado","year":"2005","unstructured":"Collado, M. et al. Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. Leuk. Res. 29, 595\u2013597 (2005).","journal-title":"Leuk. Res."},{"key":"36931_CR17","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/sj.leu.2404709","volume":"21","author":"VM Guillem","year":"2007","unstructured":"Guillem, V. M. et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 21, 1413\u20131422 (2007).","journal-title":"Leukemia"},{"key":"36931_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.4","volume":"2","author":"Y Ding","year":"2012","unstructured":"Ding, Y. et al. Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair. Blood Cancer J. 2, e58 (2012).","journal-title":"Blood Cancer J."},{"key":"36931_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1128\/MCB.19.2.1092","volume":"19","author":"M Thomas","year":"1999","unstructured":"Thomas, M. et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19, 1092\u20131100 (1999).","journal-title":"Mol. Cell. Biol."},{"key":"36931_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ijc.11548","volume":"108","author":"D Pim","year":"2004","unstructured":"Pim, D. & Banks, L. P53 Polymorphic Variants At Codon 72 Exert Different Effects on Cell Cycle Progression. Int. J. Cancer 108, 196\u2013199 (2004).","journal-title":"Int. J. Cancer"},{"key":"36931_CR21","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1038\/sj.onc.1209405","volume":"25","author":"M Siddique","year":"2006","unstructured":"Siddique, M. & Sabapathy, K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25, 3489\u20133500 (2006).","journal-title":"Oncogene"},{"key":"36931_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood-2007-11-126508","volume":"112","author":"NA Ellis","year":"2008","unstructured":"Ellis, N. A. et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 112, 741\u2013749 (2008).","journal-title":"Blood"},{"key":"36931_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nrd2656","volume":"7","author":"A Vazquez","year":"2008","unstructured":"Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979\u201387 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"36931_CR24","doi-asserted-by":"crossref","unstructured":"Bond, G. L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591\u2013602 (2004).","DOI":"10.1016\/j.cell.2004.11.022"},{"key":"36931_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1083\/jcb.146.5.905","volume":"146","author":"EP Rogakou","year":"1999","unstructured":"Rogakou, E. P., Boon, C., Redon, C. & Bonner, W. M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146, 905\u2013915 (1999).","journal-title":"J. Cell Biol."},{"key":"36931_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm.2016.111","volume":"17","author":"Y Pommier","year":"2016","unstructured":"Pommier, Y., Sun, Y., Huang, S.-Y. N. & Nitiss, J. L. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol. 17, 703\u2013721 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"36931_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4161\/trns.2.5.16813","volume":"2","author":"S Knappskog","year":"2011","unstructured":"Knappskog, S. & L\u00f8nning, P. E. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription 2, 207\u2013210 (2011).","journal-title":"Transcription"},{"key":"36931_CR28","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.4161\/cc.5.10.2799","volume":"5","author":"F Bouquet","year":"2006","unstructured":"Bouquet, F., Muller, C. & Salles, B. The loss of gammaH2AX signal is a marker of DNA double strand breaks repair only at low levels of DNA damage. Cell cycle 5, 1116\u201322 (2006).","journal-title":"Cell cycle"},{"key":"36931_CR29","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1158\/1078-0432.CCR-07-5147","volume":"14","author":"CE R\u00fcbe","year":"2008","unstructured":"R\u00fcbe, C. E. et al. DNA double-strand break repair of blood lymphocytes and normal tissues analysed in a preclinical mouse model: Implications for radiosensitivity testing. Clin. Cancer Res. 14, 6546\u20136555 (2008).","journal-title":"Clin. Cancer Res."},{"key":"36931_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep27043","volume":"6","author":"M Borr\u00e0s-Fresneda","year":"2016","unstructured":"Borr\u00e0s-Fresneda, M. et al. Differences in DNA Repair Capacity, Cell Death and Transcriptional Response after Irradiation between a Radiosensitive and a Radioresistant Cell Line. Sci. Rep. 6, 27043 (2016).","journal-title":"Sci. Rep."},{"key":"36931_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/em.20430","volume":"49","author":"O Staszewski","year":"2008","unstructured":"Staszewski, O., Nikolova, T. & Kaina, B. Kinetics of \u03b3-H2AX focus formation upon treatment of cells with UV light and alkylating agents. Environ. Mol. Mutagen. 49, 734\u2013740 (2008).","journal-title":"Environ. Mol. Mutagen."},{"key":"36931_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-4","volume":"10","author":"JP Ban\u00e1th","year":"2010","unstructured":"Ban\u00e1th, J. P., Klokov, D., MacPhail, S. H., Banuelos, C. A. & Olive, P. L. Residual \u03b3H2AX foci as an indication of lethal DNA lesions. BMC Cancer 10, 4 (2010).","journal-title":"BMC Cancer"},{"key":"36931_CR33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/mc.20633","volume":"49","author":"NV Litviakov","year":"2010","unstructured":"Litviakov, N. V. et al. Association between TP53 gene ARG72PRO polymorphism and chromosome aberrations in human cancers. Mol. Carcinog. 49, 521\u2013524 (2010).","journal-title":"Mol. Carcinog."},{"key":"36931_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/em.20635","volume":"52","author":"JL Schwartz","year":"2011","unstructured":"Schwartz, J. L. et al. Tp53 codon-72 polymorphisms identify different radiation sensitivities to g2-chromosome breakage in human lymphoblast cells. Environ. Mol. Mutagen. 52, 77\u201380 (2011).","journal-title":"Environ. Mol. Mutagen."},{"key":"36931_CR35","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/sj.embor.7400774","volume":"7","author":"F Cort\u00e9s-Ledesma","year":"2006","unstructured":"Cort\u00e9s-Ledesma, F. & Aguilera, A. Double-strand breaks arising by replication through a nick are repaired by cohesin-dependent sister-chromatid exchange. EMBO Rep. 7, 919\u2013926 (2006).","journal-title":"EMBO Rep."},{"key":"36931_CR36","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1038\/sj.onc.1207428","volume":"23","author":"A Sullivan","year":"2004","unstructured":"Sullivan, A. et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23, 3328\u20133337 (2004).","journal-title":"Oncogene"},{"key":"36931_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont, P., Leu, J. I.-J., Della Pietra, A. C., George, D. L. & Murphy, M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357\u2013365 (2003).","journal-title":"Nat. Genet."},{"key":"36931_CR38","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1096\/fj.09-146001","volume":"24","author":"B-S Jeong","year":"2010","unstructured":"Jeong, B.-S., Hu, W., Belyi, V., Rabadan, R. & Levine, A. J. Differential levels of transcription of p53-regulated genes by the arginine\/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J. 24, 1347\u20131353 (2010).","journal-title":"FASEB J."},{"key":"36931_CR39","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ng1879","volume":"38","author":"D Bergamaschi","year":"2006","unstructured":"Bergamaschi, D. et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 38, 1133\u20131141 (2006).","journal-title":"Nat. Genet."},{"key":"36931_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-249","volume":"13","author":"OV Iarovaia","year":"2014","unstructured":"Iarovaia, O. V. et al. Dynamics of double strand breaks and chromosomal translocations. Mol. Cancer 13, 249 (2014).","journal-title":"Mol. Cancer"},{"key":"36931_CR41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1200\/JCO.2003.09.072","volume":"21","author":"M Beaumont","year":"2003","unstructured":"Beaumont, M. et al. Therapy-related acute promyelocytic leukemia. J. Clin. Oncol. 21, 2123\u20132137 (2003).","journal-title":"J. Clin. Oncol."},{"key":"36931_CR42","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa042715","volume":"352","author":"AR Mistry","year":"2005","unstructured":"Mistry, A. R. et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med. 352, 1529\u20131538 (2005).","journal-title":"N. Engl. J. Med."},{"key":"36931_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cbi.2009.11.025","volume":"184","author":"Z Qian","year":"2010","unstructured":"Qian, Z. et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem. Biol. Interact. 184, 50\u201357 (2010).","journal-title":"Chem. Biol. Interact."},{"key":"36931_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrc2584","volume":"9","author":"C Whibley","year":"2009","unstructured":"Whibley, C., Pharoah, P. D. P. & Hollstein, M. P53 Polymorphisms: Cancer Implications. Nat Rev Cancer 9, 95\u2013107 (2009).","journal-title":"Nat Rev Cancer"},{"key":"36931_CR45","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/cncr.25192","volume":"116","author":"F Li","year":"2010","unstructured":"Li, F. et al. Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer 116, 2350\u20132359 (2010).","journal-title":"Cancer"},{"key":"36931_CR46","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ygyno.2006.10.008","volume":"104","author":"CS Walsh","year":"2007","unstructured":"Walsh, C. S., Miller, C. W., Karlan, B. Y. & Koeffler, H. P. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol. Oncol. 104, 660\u2013664 (2007).","journal-title":"Gynecol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36931-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36931-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36931-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T23:37:58Z","timestamp":1720913878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36931-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["36931"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-36931-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"20 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"150"}}